Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors

European Journal of Pharmacology
Pierre Van AntwerpenJean Nève

Abstract

The oxidative modification of low-density lipoproteins (LDL) is a key event in the formation of atheromatous lesions. Indeed, oxidized derivatives accumulate in the vascular wall and promote a local inflammatory process which triggers the progression of the atheromatous plaque. Myeloperoxidase (MPO) has been mentioned as a major contributor to this oxidative process. It takes part in the oxidation both of lipids by chlorination and peroxidation and of apolipoprotein B-100. Based on recent observations with several anti-inflammatory and thiol-containing drugs, the present study was designed to test the hypothesis that anti-hypertensive agents from the angiotensin converting enzyme (ACE) inhibitors group inhibit the oxidative modifications of Apo B-100 caused by MPO. Captopril, ramipril, enalapril, lisinopril and fosinopril were assessed by measuring: their inhibiting effect on the MPO/H(2)O(2)/Cl(-) system, the accumulation of compound II, which reflects the inhibition of the synthesis of HOCl and the LDL oxidation by MPO in presence of several concentrations of ACE inhibitors. Only captopril, a thiol-containing ACE inhibitor, was able to significantly decrease the oxidative modification of LDL in a dose dependent manner and thi...Continue Reading

References

Oct 20, 1995·Archives of Biochemistry and Biophysics·L K FolkesP Wardman
Jan 1, 1996·Free Radical Biology & Medicine·J A Berliner, J W Heinecke
Apr 1, 1995·Journal of Pharmaceutical and Biomedical Analysis·A JankowskiH Lamparczyk
Aug 18, 2000·Free Radical Biology & Medicine·E A PodrezS L Hazen
Aug 18, 2000·Free Radical Biology & Medicine·G M Chisolm, D Steinberg
Sep 13, 2000·International Journal of Clinical & Laboratory Research·A JerlichR J Schaur
Oct 6, 2000·Free Radical Biology & Medicine·C C Winterbourn, A J Kettle
Oct 30, 2001·Journal of Pharmaceutical and Biomedical Analysis·M GanaA Tsantili-Kakoulidou
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON
Nov 6, 2003·Redox Report : Communications in Free Radical Research·Jürgen ArnholdChristian Obinger
Sep 21, 2005·Biochemical and Biophysical Research Communications·Pierre Van AntwerpenJean Nève

❮ Previous
Next ❯

Citations

Nov 26, 2010·Nature Reviews. Nephrology·Valentina KonSergio Fazio
Mar 20, 2015·Free Radical Research·P Van Antwerpen, K Zouaoui Boudjeltia
Apr 15, 2008·Biochimica Et Biophysica Acta·Sampath ParthasarathyMahdi Garelnabi

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.